PMID- 21928360
OWN - NLM
STAT- MEDLINE
DCOM- 20120612
LR  - 20211020
IS  - 1097-0142 (Electronic)
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 118
IP  - 9
DP  - 2012 May 1
TI  - Prognostic impact of discordant results from cytogenetics and flow cytometry in 
      patients with acute myeloid leukemia undergoing hematopoietic cell 
      transplantation.
PG  - 2411-9
LID - 10.1002/cncr.26539 [doi]
AB  - BACKGROUND: Cytogenetics and multicolor flow cytometry (MFC) are useful tools for 
      monitoring outcome of treatment in acute myeloid leukemia (AML). However, no data 
      are available regarding the meaning of results when the 2 tests do not agree. 
      METHODS: The authors of this report analyzed 1464 pairs of concurrent 
      cytogenetics and flow results from 424 patients, before and after hematopoietic 
      cell transplantation, and compared the prognostic impact of discordant and 
      concordant results. RESULTS: Informative discordant results were observed in 22% 
      of patients. Compared with patients who had double-negative test results, either 
      positive result had a significant impact on overall survival and relapse-free 
      survival. The hazard ratios with either positive cytogenetic results or positive 
      MFC results pretransplantation were 3.1 (P = .009) and 2.5 (P = .0008), 
      respectively, for reduced overall survival and 2.7 (P = .01) and 4.1 (P < .0001), 
      respectively, for decreased recurrence-free survival. Similar findings were 
      obtained post-transplantation. Molecular cytogenetics, ie, fluorescence in situ 
      hybridization (FISH), added value to the evaluation of discordant cases. 
      CONCLUSIONS: The detection of residual AML by either cytogenetics or flow 
      cytometry in patients who underwent hematopoietic cell transplantation predicted 
      early relapse and shortened survival.
CI  - Copyright (c) 2011 American Cancer Society.
FAU - Fang, Min
AU  - Fang M
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, 
      Washington 98109-1023, USA. mfang@fhcrc.org
FAU - Storer, Barry
AU  - Storer B
FAU - Wood, Brent
AU  - Wood B
FAU - Gyurkocza, Boglarka
AU  - Gyurkocza B
FAU - Sandmaier, Brenda M
AU  - Sandmaier BM
FAU - Appelbaum, Frederick R
AU  - Appelbaum FR
LA  - eng
GR  - P01CA018029/CA/NCI NIH HHS/United States
GR  - P01CA078902/CA/NCI NIH HHS/United States
GR  - P01 CA078902/CA/NCI NIH HHS/United States
GR  - P30CA15704/CA/NCI NIH HHS/United States
GR  - P01 CA018029/CA/NCI NIH HHS/United States
GR  - P30 CA015704/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20110916
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Child
MH  - Child, Preschool
MH  - *Cytogenetics
MH  - Disease-Free Survival
MH  - Female
MH  - Flow Cytometry/*methods
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Infant
MH  - Infant, Newborn
MH  - Karyotyping
MH  - Leukemia, Myeloid, Acute/mortality/*therapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm, Residual/diagnosis
MH  - Recurrence
MH  - Treatment Outcome
PMC - PMC3536054
MID - NIHMS420787
COIS- Conflict-of-interest disclosure: The authors declare no competing financial 
      interests.
EDAT- 2011/09/20 06:00
MHDA- 2012/06/13 06:00
PMCR- 2013/05/01
CRDT- 2011/09/20 06:00
PHST- 2011/06/01 00:00 [received]
PHST- 2011/07/27 00:00 [revised]
PHST- 2011/08/10 00:00 [accepted]
PHST- 2011/09/20 06:00 [entrez]
PHST- 2011/09/20 06:00 [pubmed]
PHST- 2012/06/13 06:00 [medline]
PHST- 2013/05/01 00:00 [pmc-release]
AID - 10.1002/cncr.26539 [doi]
PST - ppublish
SO  - Cancer. 2012 May 1;118(9):2411-9. doi: 10.1002/cncr.26539. Epub 2011 Sep 16.